Dani Castillo· @DaniCastilloMD · X·· 3 天前评分70
正文 · 原文
As co-author, excited to share CLARITY-Gastric01 data. Sone-Ve showed a meaningful survival benefit for pts with previously treated CLDN18.2-positive GC/GEJ cancers, reinforcing CLDN18.2 as a key therapeutic target beyond the frontline setting. #ESMO2026 #GIOncology
33 浏览 · 1 赞 · 0 转发 · 0 回复
来源：Dani Castillo · x.com